JavaScript 似乎在您的浏览器中被禁用。 为了您在我们网站能获得最好的体验，建议在浏览器中打开Javascript。

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。

跳转到图像库的开头

EasySep™小鼠/人嵌合体分选试剂盒

从来源于人异种移植受体小鼠的骨髓、脾或外周血样本中通过免疫磁珠负选分离出无标记的人细胞

只有 %1 左

率先评论此产品

¥11,156.00

产品号 #（选择产品）

产品号 #19849_C

免疫磁珠负选细胞分选试剂盒

产品优势

快速、易于操作，且无需分离柱
分选得到的细胞未被标记

产品组分包括

EasySep™小鼠/人嵌合体分选试剂盒（产品号 #19849）
- EasySep™小鼠/人嵌合体分选抗体混合物，0.5mL
- EasySep™ Streptavidin RapidSpheres™ 50001磁珠，1mL
- EasySep™小鼠FcR阻断剂（产品号 #18720），0.1mL

立即询价

要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。

EasySep™缓冲液

总览

实验数据

产品说明书及文档

总览

使用 EasySep™ 小鼠/人嵌合体细胞分选试剂盒，可通过免疫磁珠负选法从人异种移植受体小鼠的骨髓、脾脏或外周血样本中轻松高效地分离高纯度的人细胞。EasySep™ 技术在已发表研究中被广泛应用超过 20 年，结合了单克隆抗体的特异性与无柱磁珠系统的简便性。

在此 EasySep™ 负选步骤中，不需要的细胞通过针对小鼠造血细胞的生物素化抗体和包被链霉亲和素的磁珠进行标记。经 EasySep™ 磁极分离后，带有磁珠标记的细胞被去除，未标记的目标细胞通过倾倒或移液方式转移至新试管中。磁珠细胞分选完成后，目标细胞可直接用于流式细胞术、培养或 DNA/RNA 提取等下游应用。

了解更多关于EasySep™ 免疫磁珠分选技术的工作原理。探索更多优化实验流程的产品，包括培养基、添加物、抗体等。

磁极兼容性
• EasySep™磁极（产品号 #18000）
• “The Big Easy” EasySep™磁极（产品号 #18001）
• EasyPlate™ EasySep™磁极（产品号 #18102）
• EasyEights™ EasySep™磁极（产品号 #18103）

分类
细胞分选试剂盒

种属
小鼠

样本来源
骨髓、脾脏、全血

分选方法
负选

应用
细胞分选

品牌
EasySep

研究领域
癌症，免疫

查看更多显示更少

Data Figures

Figure 1. Typical EasySep™ Mouse/Human Chimera Isolation Profile

In the above example, human peripheral mononuclear cells (PBMCs) are seeded into mouse bone marrow at an average starting frequency of 1.85%. The human PBMC content of the isolated fraction is 80 - 98%. Typically 3 - 4.5 log depletion of targeted mouse CD45+ is attained.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet 1

Product Name

EasySep™ Mouse/Human Chimera Isolation Kit

Catalog #

19849

Lot #

1000147889 or higher

Language

English

Document Type

Product Information Sheet 2

Product Name

EasySep™ Mouse/Human Chimera Isolation Kit

Catalog #

19849

Lot #

1000147888 or lower

Language

English

Document Type

Safety Data Sheet 1

Product Name

EasySep™ Mouse/Human Chimera Isolation Kit

Catalog #

19849

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

EasySep™ Mouse/Human Chimera Isolation Kit

Catalog #

19849

Lot #

All

Language

English

Document Type

Safety Data Sheet 3

Product Name

EasySep™ Mouse/Human Chimera Isolation Kit

Catalog #

19849

Lot #

All

Language

English

Document Type

Safety Data Sheet 4

Product Name

EasySep™ Mouse/Human Chimera Isolation Kit

Catalog #

19849

Lot #

All

Language

English

Resources and Publications

Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. A. Caye et al. Leukemia 2020 jun

Abstract

Juvenile myelomonocytic leukemia (JMML) is a rare aggressive myelodysplastic/myeloproliferative neoplasm of early childhood, initiated by RAS-activating mutations. Genomic analyses have recently described JMML mutational landscape; however, the nature of JMML-propagating cells (JMML-PCs) and the clonal architecture of the disease remained until now elusive. Combining genomic (exome, RNA-seq), Colony forming assay and xenograft studies, we detect the presence of JMML-PCs that faithfully reproduce JMML features including the complex/nonlinear organization of dominant/minor clones, both at diagnosis and relapse. Further integrated analysis also reveals that although the mutations are acquired in hematopoietic stem cells, JMML-PCs are not always restricted to this compartment, highlighting the heterogeneity of the disease during the initiation steps. We show that the hematopoietic stem/progenitor cell phenotype is globally maintained in JMML despite overexpression of CD90/THY-1 in a subset of patients. This study shed new lights into the ontogeny of JMML, and the identity of JMML-PCs, and provides robust models to monitor the disease and test novel therapeutic approaches.

View publication

Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy. X. Shi et al. Molecular therapy : the journal of the American Society of Gene Therapy 2019 nov

Abstract

Exosomes are nanosized membranous vesicles secreted by a variety of cells. Due to their unique and pharmacologically important properties, cell-derived exosome nanoparticles have drawn significant interest for drug development. By genetically modifying exosomes with two distinct types of surface-displayed monoclonal antibodies, we have developed an exosome platform termed synthetic multivalent antibodies retargeted exosome (SMART-Exo) for controlling cellular immunity. Here, we apply this approach to human epidermal growth factor receptor 2 (HER2)-expressing breast cancer by engineering exosomes through genetic display of both anti-human CD3 and anti-human HER2 antibodies, resulting in SMART-Exos dually targeting T cell CD3 and breast cancer-associated HER2 receptors. By redirecting and activating cytotoxic T cells toward attacking HER2-expressing breast cancer cells, the designed SMART-Exos exhibited highly potent and specific anti-tumor activity both in vitro and in vivo. This work demonstrates preclinical feasibility of utilizing endogenous exosomes for targeted breast cancer immunotherapy and the SMART-Exos as a broadly applicable platform technology for the development of next-generation immuno-nanomedicines.

View publication

View All Publications

物种	小鼠
Magnet Compatibility	• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • EasyPlate™ EasySep™ Magnet (Catalog #18102)
样本来源	全血, 脾脏, 骨髓
Selection Method	Negative